Latent Labs

🔬 Mini-binders represent a new therapeutic modality — for targeted delivery, diagnostics, and therapeutic inhibitors.

For partnerships: partnerships@latentlabs.com

🚀 Available now on the Latent Labs Platform with free tier access:

* No-code interface
* Upload targets, select epitopes, generate binders
* 10x faster than previous methods
* Computational ranking for lab prioritization

🧪 Lab-validated target specificity across all tested mini-binders.

See the all-against-all binding screen via our in-house mDisplay assay below:

⚡ Watch Latent-X generate a picomolar mini-binders from scratch — solving the geometric puzzle of binding at the all-atom level in real-time.

Every atom placed with precision to create the biochemistry required for tight, specific binding.

🔬 Look at the generated non-covalent bonds — hydrogen bonds, pi-stacking, van der Waals interactions.

Latent-X doesn't just predict binding; it generates the exact biochemical interactions needed for high affinity and specificity.

🎯 Extensive lab validation shows leading performance:

* 100% target success rate (5/5 therapeutically relevant proteins)
* Picomolar binding affinities achieved
* 10-64% experimental hit rates
* Testing just ~100 designs per target vs millions traditionally

🧬Latent-X is our first frontier model for protein design.

For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.

Explore our best binders here: platform.latentlabs.com

More details on the breakthrough in this🧵

In extensive wet lab experiments, Latent-X achieved what would typically require millions of candidates by testing as little as 30-100 candidates per target—yet achieved strong binding affinities down to the picomolar ranges.

Sign-up for early access at: platform.latentlabs.com

Latent Labs launches web-based AI model to democratize protein design | TechCrunch The company claims that its model achieved state of the art on specific metrics.

‘Latent Labs launches web-based AI model to democratize protein design.’

Thank you @techcrunch.com and Marina Temkin for the coverage.

Read the full story: tinyurl.com/Latent-X-Tec...

Starting with macrocycles and mini-binders, expanding to nanobodies and more. Our mission: make biology programmable to make drug design instantaneous.
Join early access: platform.latentlabs.com
Technical report: tinyurl.com/latent-X
Technical details: www.latentlabs.com/latent-x

Latent-X solves the geometric puzzle of binding at the all-atom level, generating novel binders from scratch while obeying nature's biochemical rules.
Scientists can now access lab-validated AI workflows without needing AI expertise or infrastructure.

Traditional drug discovery screens millions of random molecules with <1% hit rates. Latent-X flips this: we generate 30-100 precise designs per target and achieve lab success rates up to 100%.

The efficiency gains are dramatic.

5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design.

Available now on our no-code platform!

Learn more about the panel and the event here: uspharma.live.ft.com/agenda/sessi...

Catch @saakohl.bsky.social's panel with Glen Gowers, Michael Curtis, Amber Salzman, and Oliver Barnes at the @financialtimes.com Biotech Summit this Thursday discussing what the future holds for AI-driven drug discovery.

Latent Labs and AWS announce collaboration to scale generative AI for the Life Sciences - Latent Labs

Read more about how we’re working with AWS to put AI directly into the hands of biologists, pharma, and biotech innovators around the world: shorturl.at/0t63L

Latent Labs is partnering with @awscloud.bsky.social to super‑charge generative AI for the life sciences. Together, we’ll scale access to protein design tools that help scientists discover breakthrough therapies faster.

Founded by DeepMind alumnus, Latent Labs launches with $50M to make biology programmable | TechCrunch A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

"Latent Labs is building AI foundation models to 'make biology programmable', partnering with biotech and pharma to generate and optimize proteins."
Huge thanks to @techcrunch.com, our investors & supporters. Follow us as we push the frontiers of AI & biology.
techcrunch.com/2025/02/12/f...

How Latent Labs Plans To Create Medicines From Scratch With AI Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for drug discovery and development

"What if scientists could create the building blocks of new medicines completely from scratch, targeting diseases with precisely designed cures?"

Thank you @forbes.com & @davidprosser for the coverage:
www.forbes.com/sites/davidp...

Google star raises $50 million to use AI to design proteins Latent Labs founder Simon Kohl, a former member of the internet giant’s DeepMind team, has a new target

"One of DeepMind’s Nobel-prize winning AlphaFold team has raised $50 million to launch his own venture designing new proteins, with the goal of “achieving computational mastery over biology”."
Thank you @thetimes.com and @richardtyler for featuring us: www.thetimes.com/business-mon...

Ex-DeepMind scientist launches AI drug discovery venture Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system

"Simon Kohl, a scientist, has raised $50M to launch a startup to discover new drugs."
We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social.
www.ft.com/content/9214...

I loved my time at DeepMind working on AlphaFold2 and to be there in Stockholm to watch Demis Hassabis and John Jumper accept the Nobel Prize was incredible.

We’ve built an exceptional founding team – and are hiring in London and San Francisco! Come join the likes of Alex Bridgland (AlphaFold 1, 2 & 3), Annette Obika-Mbatha (multiple DeepMind programs), Dave Yuan (Mammoth Bio) and amazing people from Microsoft, Google, Altos Labs, Stability AI and more.

Our Angels include Google Chief Scientist @jeffdean.bsky.social, Transformer architecture co-inventor and Cohere founder @aidangomez.bsky.social, and ElevenLabs founder Mati Staniszewski.

The funding includes our Series A co-led by Radical Ventures and Sofinnova Partners, with existing investors Pillar VC, Kindred Capital and 8VC participating alongside new investors Isomer Capital and Flying Fish.

Every biotech or pharma company searching for the best therapeutic molecules understands the role AI can play - but not all are in a position to develop their own advanced models. That’s where @latentlabs.bsky.social comes in.

Apply to access our tools or join the team www.latentlabs.com

It is clear protein design has the potential to transform medicine and scientific discovery. I believe Latent Labs will be the team to fully realize its potential. It’s a vast field and there’s so much still to do. Let’s go!

We are out of stealth with $50M in funding.

Join us on our moonshot mission of making biology programmable and reach out to work with us today.